Rockwell Medical (RMTI) Upgraded by ValuEngine to “Hold”

Rockwell Medical (NASDAQ:RMTI) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

Other analysts have also issued reports about the company. BidaskClub upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Thursday, May 31st.

Shares of NASDAQ:RMTI opened at $4.41 on Wednesday. Rockwell Medical has a 1 year low of $3.62 and a 1 year high of $8.70. The firm has a market cap of $272.30 million, a P/E ratio of -8.65 and a beta of 2.19.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Thursday, May 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Rockwell Medical had a negative return on equity of 76.49% and a negative net margin of 48.06%. The business had revenue of $14.95 million during the quarter. analysts predict that Rockwell Medical will post -0.39 EPS for the current year.

Several large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its holdings in shares of Rockwell Medical by 117.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 27,139 shares of the company’s stock worth $158,000 after acquiring an additional 14,648 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Rockwell Medical by 21.9% during the first quarter. Schwab Charles Investment Management Inc. now owns 95,900 shares of the company’s stock worth $500,000 after acquiring an additional 17,200 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of Rockwell Medical during the fourth quarter worth $110,000. BlackRock Inc. raised its holdings in shares of Rockwell Medical by 0.8% during the fourth quarter. BlackRock Inc. now owns 3,049,031 shares of the company’s stock worth $17,746,000 after acquiring an additional 23,899 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Rockwell Medical during the fourth quarter worth $217,000. Institutional investors and hedge funds own 21.21% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply